Our goal is to understand the mechanisms and regulation of gene amplification in mammalian cells. The primary mechanisms of amplification involve recombination rather than over-replication. Unequal distribution of the recombined chromosomes into two daughter cells leads to an increase in gene copy number in one (amplification) and a decrease in the other (genetic loss). Thus the same basic process is also likely to be responsible, at least in part, for the loss of tumor suppressor alleles in cancer. Mechanisms. The primary events of amplification seem to be region- specific recombinations between sister chromatids involving T-T, C-C and possibly C-T pairings. The first amplified structures formed at several different loci in several different species will be studied and the novel joints will be identified. Recombination reactions involving these sequences will be studied in mammalian cells. Permissivity. Normal cell strains do not give stable drug-resistant colonies containing amplified DNA whereas most immortalized cells give such colonies readily. Cooperating oncogenes confer permissivity on amplification-negative cells. What normal proteins interact with these oncogene products? The roles of temperature-sensitive or conditionally expressed oncogenes such as the SV40 large T antigen and tumor suppressor genes such as p53 will be explored. Stimulation. Cell lines that amplify genes at a significant rate can be stimulated to increase that rate transiently by many treatments that damage DNA or arrest DNA synthesis, or stably in spontaneous """"""""amplificator"""""""" mutants. Genes whose products stimulate amplification will be cloned by expression. The clones will be used to explore how stimulated amplifications occur.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM049345-03
Application #
2186936
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1993-09-01
Project End
1997-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
017730458
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Hastak, Kedar; Paul, Rajib K; Agarwal, Mukesh K et al. (2008) DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation. Proc Natl Acad Sci U S A 105:6314-9
Jackson, Mark W; Patt, Linnea E; LaRusch, Gretchen A et al. (2006) Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells. J Biol Chem 281:16814-20
Patton, John T; Mayo, Lindsey D; Singhi, Aatur D et al. (2006) Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 66:3169-76
Chernova, O B; Chernov, M V; Ishizaka, Y et al. (1998) MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification. Mol Cell Biol 18:536-45
Chernov, M V; Stark, G R (1997) The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. Oncogene 14:2503-10